GlobeNewswire (Fri, 3:06PM)
There are no Focus articles on CYDY.
There are no Related articles on CYDY.
There are no Transcripts on CYDY.
CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIVGlobeNewswire (Jul 31, 2014)
We currently have no Breaking News on this stock.
There are no StockTalks on this stock yet.
CYDY vs. ETF Alternatives
CytoDyn is a publicly traded biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn's lead product candidate, PRO 140, has the potential to drive groundbreaking advancements in developing the next generation of HIV... More
Other News & PR